Corcept's Phase IV win changes mood music after ALS flop

US biotech Corcept Therapeutics (Nasdaq: CORT) has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes.

Also known as Cushing’s syndrome, hypercortisolism is a condition caused by prolonged exposure to high levels of cortisol, leading to obesity, hypertension, and potentially life-threatening complications.

Corcept said the trial met its primary endpoint, demonstrating significant improvements in blood sugar levels. People in the study had diabetes which was uncontrolled despite optimal therapies, including GLP-1 agonists.